Literature DB >> 19070991

Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study.

Diego Novick1, Josep Maria Haro, David Suarez, Eduard Vieta, Dieter Naber.   

Abstract

Recovery is an important outcome of schizophrenia that has not been well defined or researched. Using a stringent definition of recovery that included long-lasting symptomatic and functional remission as well as an adequate quality of life for a minimum of 24 months and until the 36-month visit, we determined the frequency and predictors of recovery in patients with schizophrenia during 3 years of antipsychotic treatment in the prospective, observational Schizophrenia Outpatients Health Outcomes (SOHO) study. Of the 6642 patients analysed, 33% achieved long-lasting symptomatic remission, 13% long-lasting functional remission, 27% long-lasting adequate quality of life, and 4% achieved recovery during the 3 year follow-up period. Logistic regression analysis revealed that social functioning at study entry (having good occupational/vocational status, living independently and being socially active) and adherence with medication were factors significantly associated with achieving recovery. Higher negative symptom severity, higher BMI and lack of effectiveness as the reason for change of medication at baseline were baseline factors associated with a lower likelihood of achieving recovery. Treatment with olanzapine was also associated with a higher frequency of recovery compared with risperidone, quetiapine, typical antipsychotics (oral, depot) and patients taking two or more antipsychotic medications. There were no differences among the patients taking olanzapine, clozapine and amisulpride. Predictors of long-lasting symptomatic remission, functional remission and adequate quality of life were also independently analysed. Although the results should be interpreted conservatively due to the observational, non-randomised study design, they indicate that only a small proportion of patients with schizophrenia achieve recovery and suggest that social functioning, medication adherence and type of antipsychotic are important predictors of recovery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19070991     DOI: 10.1016/j.schres.2008.11.007

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  24 in total

Review 1.  Functional outcomes in schizophrenia: employment status as a metric of treatment outcome.

Authors:  Rebecca Schennach; Richard Musil; Hans-Jürgen Möller; Michael Riedel
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

2.  Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial.

Authors:  Rebecca Schennach; Michael Riedel; Michael Obermeier; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Florian Seemüller; Hans-Jürgen Möller
Journal:  Psychiatr Q       Date:  2012-06

3.  Remission and recovery during the first outpatient year of the early course of schizophrenia.

Authors:  Joseph Ventura; Kenneth L Subotnik; Lisa H Guzik; Gerhard S Hellemann; Michael J Gitlin; Rachel C Wood; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2011-07-18       Impact factor: 4.939

4.  Imagining the future: degraded representations of future rewards and events in schizophrenia.

Authors:  Erin A Heerey; Tatyana M Matveeva; James M Gold
Journal:  J Abnorm Psychol       Date:  2011-05

5.  Cognitive and symptomatic predictors of functional disability in schizophrenia.

Authors:  Syed Shamsi; Adam Lau; Todd Lencz; Katherine E Burdick; Pamela DeRosse; Ron Brenner; Jean-Pierre Lindenmayer; Anil K Malhotra
Journal:  Schizophr Res       Date:  2010-09-15       Impact factor: 4.939

6.  Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia.

Authors:  H K Luckhoff; S Kilian; M R Olivier; L Phahladira; F Scheffler; S du Plessis; B Chiliza; L Asmal; R Emsley
Journal:  Metab Brain Dis       Date:  2019-01-02       Impact factor: 3.584

Review 7.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

8.  Atypical antipsychotics in the treatment of depressive and psychotic symptoms in patients with chronic schizophrenia: a naturalistic study.

Authors:  Marco Innamorati; Stefano Baratta; Cristina Di Vittorio; David Lester; Paolo Girardi; Maurizio Pompili; Mario Amore
Journal:  Schizophr Res Treatment       Date:  2013-01-21

Review 9.  Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.

Authors:  Giuseppe Rossi; Sonia Frediani; Roberta Rossi; Andrea Rossi
Journal:  BMC Psychiatry       Date:  2012-08-21       Impact factor: 3.630

10.  Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study.

Authors:  Bernardo Carpiniello; Federica Pinna; Massimo Tusconi; Enrico Zaccheddu; Francesca Fatteri
Journal:  Schizophr Res Treatment       Date:  2012-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.